Analysis of Transcription Factors Key for Mouse Pancreatic Development Establishes NKX2-2 and MNX1 Mutations as Causes of Neonatal Diabetes in Man

Sarah E. Flanagan,1 Elisa De Franco,1 Hana Lango Allen,1 Michele Zerah,2 Majedah M. Abdul-Rasoul,3 Julie A. Edge,4 Helen Stewart,5 Elham Alamiri,6 Khalid Hussain,7 Sam Wallis,8 Liat de Vries,9 Oscar Rubio-Cabezas,1,10 Jayne A.L. Houghton,1 Emma L. Edghill,1 Ann-Marie Patch,1 Sian Ellard,1 and Andrew T. Hattersley1,4

1Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter EX2 5DW, UK
2Presbyterian Medical Group, Albuquerque, NM 87106, USA
3Faculty of Medicine, Department of Pediatrics, Kuwait University, Safat 13110, Kuwait
4Oxford Children’s Hospital, Headington, Oxford OX3 9DU, UK
5Department of Clinical Genetics, Oxford University Hospitals NHS Trust, Oxford OX3 7LE, UK
6Al Qassimi Hospital, Sharjah 3500, United Arab Emirates
7London Centre for Paediatric Endocrinology and Metabolism, Great Ormond Street Hospital for Children NHS Trust, and The Institute of Child Health, University College London, London WC1N 1EH, UK
8Neonatal Unit, Bradford Royal Infirmary, Bradford BD9 6RU, UK
9Institute of Endocrinology and Diabetes, Schneider Children’s Medical Center of Israel, PetahTikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 49202, Israel
10Department of Paediatric Endocrinology, Hospital Infantil Niño Jesús, Madrid 28009, Spain
*Correspondence: a.t.hattersley@exeter.ac.uk
http://dx.doi.org/10.1016/j.cmet.2013.11.021

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Open access under CC BY license.

SUMMARY

Understanding transcriptional regulation of pancreatic development is required to advance current efforts in developing beta cell replacement therapies for patients with diabetes. Current knowledge of key transcriptional regulators has predominantly come from mouse studies, with rare, naturally occurring mutations establishing their relevance in man. This study used a combination of homoygosity analysis and Sanger sequencing in 37 consanguineous patients with permanent neonatal diabetes to search for homozygous mutations in 29 transcription factor genes important for murine pancreatic development. We identified homozygous mutations in 7 different genes in 11 unrelated patients and show that NKX2-2 and MNX1 are etiological genes for neonatal diabetes, thus confirming their key role in development of the human pancreas. The similar phenotype of the patients with recessive mutations and mice with inactivation of a transcription factor gene support there being common steps critical for pancreatic development and validate the use of rodent models for beta cell development.

INTRODUCTION

Knowledge on transcriptional regulators of pancreatic development and beta cell differentiation is essential for the development of beta cell replacement therapies for diabetes (Kroon et al., 2008; Zhou et al., 2008). While major work has been undertaken in mice, the extent to which murine pancreatic development is a good model for man is not fully understood.

Finding inactivating mutations in patients with diabetes can establish the role of a gene in human pancreatic development and function. Comparing the human phenotype with mouse models for the same gene is important, as it validates that the gene function is similar in man and mouse. Concordant phenotypes between mouse models with biallelic gene inactivation and humans with biallelic mutations suggest similar function of the gene product in rodents and man. For example, biallelic GCK mutations in humans cause permanent neonatal diabetes (PNMD), and mice lacking both copies of the gene have severe hyperglycemia at birth (Njolstad et al., 2001; Terauchi et al., 1995). Both patients with recessive EIF2AK3 mutations and the Perk null mouse (EIF2ak3−/−) develop diabetes due to destruction of beta cells as a result of endoplasmic reticulum stress (Delépine et al., 2000; Harding et al., 2001; Zhang et al., 2002).

The correlation in phenotype between knockout mice and humans with recessive mutations is not always evident. Biallelic loss-of-function ABCC8 mutations are the most common known cause of hyperinsulinemic hypoglycemia in humans, whereas ABCC8 null mice maintain euglycemia (Shiota et al., 2002; Thomas et al., 1995). GLUT2 has been shown to be the primary glucose transporter and sensor in rodent pancreatic islets, whereas studies in humans have suggested that GLUT1 plays an important role in facilitating glucose entry into the developing beta cell (De Vos et al., 1995; McCulloch et al., 2011). An example of a difference at the level of the gene structure is the insulin gene: in humans preproinsulin is encoded by a single
gene (INS), while in mice two functional copies of the gene exist (Ins1 and Ins2).

Studies investigating transcriptional regulation of beta cell development in mice have, however, been successful in identifying pancreatic transcription factor genes important for human pancreatic development. Much of the mouse work has involved the complete or targeted (conditional) knockout of a gene followed by detailed phenotypic studies during embryonic development and, when viable, in the resulting live offspring. To date, mutations in eight different pancreatic transcription factor genes (PDX1, PTF1A, GLIS3, PAX6, RFX6, NEUROD1, NEUROG3, GATA6) have been identified in patients with neonatal diabetes (Lango Allen et al., 2012; Rubio-Cabezas et al., 2010, 2011; Sellick et al., 2004; Senée et al., 2006; Smith et al., 2010; Solomon et al., 2009; Stoffers et al., 1997). For some transcription factor genes the genetic etiology in the patients was initially recognized from the similarity to the mouse phenotype (Rubio-Cabezas et al., 2010; Stoffers et al., 1997). Mutations causing a pancreatic/diabetes phenotype have not been found in man for many pancreatic transcription factors important for rodent pancreatic development, but there have been no large, systematic studies of these genes in appropriate patients to date.

The aim of our study was to perform a comprehensive search for recessive mutations in genes encoding transcription factors known to be critical for pancreatic development in mice in a large collection of PNDM patients born to consanguineous parents. Patients with consanguineous parents were chosen, as the likelihood of a recessive cause of their PNDM is greatly increased (Rubio-Cabezas et al., 2009), and all mouse models of transcription factors influencing pancreatic development involve biallelic inactivation. We tested for mutations in homozygous regions encompassing known transcription factor genes independently of the clinical features to avoid the possible bias introduced when clinical features guide candidate gene testing.

**RESULTS AND DISCUSSION**

We studied 147 patients from consanguineous pedigrees. Mutations in non-transcription factor genes were identified in 110 probands (75%) (Table 1, Figure S1, and Table S1). Systematic investigation of 29 transcription factor genes important for murine pancreatic development identified homozygous mutations in 7 genes in 12 patients from 11 families (30% of the investigated patients), resulting from heterozygous null mutations in 3 genes. Cosegregation studies were consistent with recessive inheritance (Figure 1A). No heterozygous or homozygous truncating mutations have been reported in 6,500 individuals sequenced by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/). All three patients have severe defects in insulin secretion, as shown by intrauterine growth retardation (IUGR) and presentation of diabetes at an early age without features of pancreatic exocrine dysfunction (Table 2). This is very similar to mice that are homozygous for a targeted disruption of Nkx2-2 and die shortly after birth with severe hyperglycemia (Briscoe et al., 1999; Susse et al., 1998) (Table 2). They have normal exocrine function, lack beta cells, and have fewer alpha and pancreatic polypeptide cells (Susse et al., 1998). The patients with homozygous null mutations in Nkx2-2 also have severe developmental delay, which affects both motor and intellectual function as well as more specific features, such as hypotonia, cortical blindness, impaired visual tracking, and hearing impairment. These are consistent with the severe neurological features seen in the Nkx2-2 knockout mouse (Table 2) and Nkx2-2 being essential for hindbrain development, ventral neuronal patterning, and oligodendrocyte differentiation (Briscoe et al., 1999; Qi et al., 2001).

**Homozygous Mutations in MNX1 Cause Neonatal Diabetes**

Two probands have homozygous missense mutations in MNX1 (previously described as HIXB9). The p.F248L and p.F272L missense mutations are highly likely to be pathogenic, as they cosegregate with neonatal diabetes (Figure 1B), affect highly conserved residues within the homeodomain (Table 2, Figure 1C), are not listed in 6,500 individuals sequenced by the NHLBI Exome Sequencing Project, and in silico analysis predicted the mutations to be disease causing. Our results are in line with the recently published paper by Bonnefond et al. (2013), who independently found the same MNX1 p.F272L mutation in proband 2. Both probands in our study had severe intrauterine growth retardation and were diagnosed with diabetes in infancy without evidence of exocrine pancreatic dysfunction. This is similar to the MNX1 null mice that are born smaller than their wild-type littermates and have small islets and reduced numbers of beta cells and normal exocrine function (Table 2) (Harrison et al., 1999). These mice also have dorsal lobe agenesis of the pancreas; it is not known if this is a feature of our two patients, as imaging and post mortem investigations were not performed. Proband 1 (but not proband 2) had marked extrapancreatic developmental features, including severe neurological complications and hypoplastic lungs (respiratory failure caused death at 10 months) (Table 2). In keeping with these observations, MNX1 null mice have aberrant motor neuron differentiation but are difficult to study as they die at birth due to respiratory paralysis, which probably results from failure in the development of the phrenic nerve (Thaler et al., 1999). The variability in phenotype between the two probands could be due to differences in the severity of their mutations, but further studies investigating the functional consequences of these missense mutations are required in order to explore this hypothesis.

Proband 1 also had sacral agenesis and a high imperforate anus, which are both cardinal features of Currarino syndrome (OMIM #176450), resulting from heterozygous MNX1 mutations (Currarino et al., 1981; Ross et al., 1998). Mice homozygous for a null mutation do not have skeletal defects (Harrison et al., 1999). Proband 2 and his heterozygous relatives do not have features of Currarino syndrome. The highly variable phenotype is not unexpected, as around 50% of homozygous carriers are
clinically asymptomatic (Köchling et al., 2001). As diabetes is not a feature of Currarino syndrome, it seems likely that a single copy of \( \text{MNX1} \) is sufficient to maintain normal pancreatic development and glucose homeostasis, a hypothesis that is further supported by the observation that heterozygous mice have a normal pancreas (Harrison et al., 1999).

### Table 1. Pancreatic Transcription Factor Gene Analysis in Patients with Neonatal Diabetes, Related to Tables S1 and S2

| Gene   | Diabetes Phenotype | Number of Homozygous Regions in 37 Patients | Mutations Identified in PNDM Patients | Homozygous Region Coordinates | Homozygous Mutations Identified | Reference(s) in which Patient Was Previously Reported |
|--------|--------------------|-------------------------------------------|-------------------------------------|--------------------------------|--------------------------------|------------------------------------------------|
| FOXA1  | –                  | 2                                         | 0                                   | –                              | –                              | –                                             |
| FOXA2  | embryonic lethal   | 1                                         | 0                                   | –                              | –                              | –                                             |
| GATA4  | embryonic lethal   | 2                                         | 0                                   | –                              | –                              | –                                             |
| GATA6  | embryonic lethal   | 3                                         | 0                                   | –                              | –                              | –                                             |
| GLIS3  | neonatal diabetes  | 4                                         | 2                                   | chr9: 36,587–4,187,290 chr9: 39,094,547–46,744,084 | –                              | Dimitri et al., 2011 |
| HES1   | pancreatic hypoplasia | 2                                      | 0                                   | –                              | –                              | –                                             |
| HHEX   | pancreatic hypoplasia | 1                                      | 0                                   | –                              | –                              | –                                             |
| HNF1B  | embryonic lethal   | 1                                         | 0                                   | –                              | –                              | –                                             |
| INSM1  | neonatal lethal    | 2                                         | 0                                   | –                              | –                              | –                                             |
| ISL1   | pancreatic hypoplasia | 2                                      | 0                                   | –                              | –                              | –                                             |
| MAFA   | diabetes at 8–12 weeks | 0                                   | 0                                   | –                              | –                              | –                                             |
| MAFB   | neonatal lethal    | 4                                         | 0                                   | –                              | –                              | –                                             |
| MNX1   | pancreatic hypoplasia | 10                                     | 2                                   | chr7: 147,339,570–158,659,419 chr7: 155,022,291–158,811,981 | p.F248L (c.744C > G) p.F272L (c.916C > A) | Bonnefond et al., 2013 |
| NEUROD1 | neonatal diabetes | 3                                         | 1                                   | –                              | p.D122fs (c.364 dupG) | Rubio-Cabezas et al., 2010 |
| NEUROG3 | neonatal diabetes | 1                                         | 0                                   | –                              | –                              | –                                             |
| NKX2.2 | neonatal diabetes  | 2                                         | 2                                   | chr20: 4,435,760–60,974,283 chr20: 19,494,958–32,325,488 | p.P119fs (c.356 del) p.R129X (c.385C > T) | –                                             |
| NKX3.2 | –                  | 4                                         | 0                                   | –                              | –                              | –                                             |
| NKX6.1 | reduced insulin secretion | 2                                    | 0                                   | –                              | –                              | –                                             |
| NKX6.2 | –                  | 4                                         | 0                                   | –                              | –                              | –                                             |
| ONECUT1 | adult-onset diabetes | 3                                      | 0                                   | –                              | –                              | –                                             |
| PA4    | neonatal diabetes  | 1                                         | 0                                   | –                              | –                              | –                                             |
| PAX6   | neonatal lethal    | 0                                         | 0                                   | –                              | –                              | –                                             |
| PDX1   | pancreatic agenesis | 4                                         | 2                                   | chr13: 27,258,487–42,966,967 chr13: 21,702,312–43,640,426 | p.A152G (c.455C > G) p.R176Q (c.527G > A) | De Franco et al., 2013 |
| PTF1A  | pancreatic agenesis | 8                                         | 1                                   | chr10: 14,877,485–49,578,351    | p.? (c.784 + 4A > G) | Lango Allen et al., 2012 |
| RBPJ   | embryonic lethal   | 2                                         | 0                                   | –                              | –                              | –                                             |
| RBPJL  | –                  | 4                                         | 0                                   | –                              | –                              | –                                             |
| RFX6   | neonatal diabetes  | 5                                         | 1                                   | chr6: 109,613,154–144,987,523  | p.S217P (c.649T > C) | Smith et al., 2010 |
| SOX17  | embryonic lethal   | 1                                         | 0                                   | –                              | –                              | –                                             |
| SOX9   | embryonic lethal   | 6                                         | 0                                   | –                              | –                              | –                                             |

Transcription factor genes important for murine pancreatic development and the resulting diabetes phenotype in null mice. Genome-wide SNP typing identified 84 homozygous regions encompassing a transcription factor gene in 30 patients with permanent neonatal diabetes. Using Sanger sequencing, 11 mutations were detected in 7 of these genes.
|                  | NKX2-2 Homozygous Null Mouse* | Humans | MNX1 Homozygous Null Mouse* | Humans |
|------------------|--------------------------------|--------|-----------------------------|--------|
|                  | Proband 1 (p.P119fs)          | Sibling (p.P119fs) | Proband 2 (p.R129X) | Proband 1 (p.F248L) | Proband 2 (p.F272L) |
| Gender           | female                        | male   | female                      | male   |
| Current age (years) | 5.5                            | 1.5    |                            |                |
| Birth weight (gestation) | 1.36 kg (35 weeks) | 1.68 kg (40 weeks) | 1.22 kg (37 weeks) |                |
| Birth weight (SDS) | not distinguishable from wild-type littermates at birth | −2.8  | −3.64                       | −4.52  |
| Pancreatic Features | Age diagnosis (days) | 2      | 2                           | 7      |
|                  | Glucose at presentation (mmol/l) | 23 (4.5 wild-type littermates) | 18    | not available | 67    |
|                  | Current insulin requirement (U/kg/day) | − | 0.57                        | 0.60  |
|                  | Current HbA1c (%) (mmol/mol) | − | 9% (75)                     | 7.9% (63) | 9.5%–12% (80–108) |
| Evidence of exocrine insufficiency | no                          | no    | no                         | no    |
| Extrapancreatic Features | CNS retardation oligodendrocyte differentiation and absence of hindbrain serotonergic neurons | severe developmental delay (unable to stand or talk at 5 years of age), hypotonia, cortical blindness, thin corpus callosum and generalized gliosis on MRI | severe developmental delay (motor function is that of a 5 month old at 9 months of age) | moderate developmental delay (walks with assistance at 11 years of age), hypotonia, inability to fix gaze and follow, bilateral hearing impairment |
|                  | Growth | growth retarded           | short stature (−3 SDS) | − | short stature (−2.2 SDS) |
|                  | Additional features | none reported | swallowing difficulties, severe constipation | constipation | none reported |
|                  | MNX1 Homozygous Null Mouse* | Humans | Proband 1 (p.F248L) | Proband 2 (p.F272L) |
| Gender           | – | male | female |
| Current Age      | – | deceased at an age of 10 months | 3 years |
| Birth weight (gestation) | IUGR | 2.23 kg (40 weeks) | 1.90 kg (38 weeks) |
| Birth weight (SDS) | − | −2.54 | −3.09 |
| Pancreatic Features | Age at diagnosis of diabetes (weeks) | dorsal lobe agenesis, small islets, reduced number of beta cells | 30 | 1 |
|                  | Glucose at presentation (mmol/l) | – | 12.1 | 35 |
|                  | Insulin requirement | – | 0.3 U/kg/day | 0.8 U/kg/day |
|                  | HbA1c% | − | 6.6% (49) | 7.8% (62) |
| Evidence of exocrine insufficiency | no | no | no |

(Continued on next page)
Homozygous mutations in five pancreatic transcription factor genes previously reported to cause PNDM were identified in seven probands. The phenotype of these patients is similar to that seen in mice with biallelic inactivation of these genes (Table 3). Our two patients with GLIS3 mutations, the six previous cases (Dimitri et al., 2011; Senée et al., 2008), and the Glis3 mouse knockout (Watanabe et al., 2009) all have neonatal diabetes diagnosed in the first week of life and congenital hypothyroidism. We identified one patient with a homozygous NEUROD1 mutation. Both this patient and a previously reported case from a nonconsanguineous pedigree (Rubio-Cabezas et al., 2010) have neonatal diabetes, neurodevelopmental delay, cerebellar hypoplasia, and hearing and visual impairment. The Neurod1 null mouse also has neonatal diabetes and severe neurological defects, including impaired coordination and ataxia, cerebellar hypoplasia, sensorineural deafness, and retinal blindness (Liu et al., 2000; Miyata et al., 1999; Morrow et al., 1999; Naya et al., 1997; Pennesi et al., 2003). The proband with a homozygous RFX6 mutation was diagnosed with diabetes at 8 days and had duodenal atresia and gall bladder agenesis. This is consistent with the previous five cases and the Rfx6 knockout mouse, which has neonatal diabetes and small bowel atresia (Smith et al., 2010).

Two probands with homozygous PDX1 (previously described as IPF1) missense mutations had isolated PNDM. In both man and mouse, the severity of the PDX1 mutation determines the pancreatic phenotype. Pancreatic agenesis was seen in the mouse knockout (Jonsson et al., 1994) and in patients with two copies of a severe mutation (Fajans et al., 2010; Schwitzgebel et al., 2003; Stoffers et al., 1997, 1998; Thomas et al., 2009). In mice, hypomorphic mutations are associated with diabetes without evidence of exocrine deficiency (Oliver-Krasinski et al., 2009); we and others have shown that patients with less-severe homozygous missense mutations have neonatal diabetes with normal or mildly impaired exocrine function (De Franco et al., 2013; Nicolino et al., 2010).

An intronic PTF1A mutation (c.784 + 4A > G) was identified in a proband with pancreatic agenesis. This mutation is predicted to result in an alternative splice donor site (Alamut Interactive Biosoftware, version 2.1) and the inclusion of an additional 4 bases in the mRNA, causing a frameshift and premature termination codon at residue 271. The pancreatic phenotype is similar to the three previously reported patients with nonsense or frameshift mutations and the Ptf1a null mouse (Al-Shammari et al., 2011; Krapp et al., 1998; Sellick et al., 2004). Our patient has mild learning difficulties at 15 years old, which is in contrast to the other patients who had severe neurological features, causing death before 4 months of age. These patients and the knockout mouse had cerebellar aplasia. In a mouse model, reduced Ptf1a gene dosage results in pancreatic hypoplasia and glucose intolerance in a dose-dependent manner (Fukuda et al., 2008). We hypothesize that the absence of cerebellar agenesis in this patient may reflect a reduced functional severity of the splicing mutation compared to previously reported null mutations.

The finding that mutations in NKX2-2 and MNX1 can cause neonatal diabetes takes the number of genes in which mutations are known to cause PNDM from 18 to 20, of which 10 encode pancreatic transcription factors. Unlike previous studies, which
have identified mutations in humans because of similarities in phenotype with the null mouse, our systematic approach guided by areas of linkage has allowed us to screen all transcription factor genes independently of clinical features. Our results confirm that the consequence of inactivation of pancreatic transcription factor genes in humans is similar to the phenotype observed in knockout mice. This is in contrast to heterozygous loss-of-function mutations where differences in phenotype have been observed. For example, monoallelic mutations in \textit{GATA6} or \textit{HNF1B} cause pancreatic agenesis with congenital heart defects or renal cysts with diabetes, respectively, while mice heterozygous for a null mutation in \textit{Gata6} or \textit{Hnf1b} show no obvious phenotype (Bingham et al., 2001; Haumaitre et al., 2005; Lango Allen et al., 2012; Morrisey et al., 1998).

There are some limitations to our study. The minimum prevalence of transcription factor mutations in our cohort of patients with consanguineous PNDM was 7.5\%, but the true prevalence may be slightly higher since heterozygous or compound heterozygous mutations would have been missed as a result of the study design. However, as all of the patients were known to be consanguineous, the prior probability is that they have recessively inherited disease due to a homozygous mutation. While the identification of patients with homozygous inactivating mutations in pancreatic transcription factor genes has confirmed their role in human organogenesis, these findings can only provide limited information on pancreatic development, as detailed physiological studies in man are not always possible. This is especially true for the patients within our cohort with \textit{NKX2-2} and \textit{MNX1} mutations that are all currently under 13 years of age and, for those with \textit{NKX2-2} mutations, have severe developmental delay, which means that in-depth studies on pancreatic and neurological function are not possible.

In conclusion, we have shown that mutations in \textit{NKX2-2} and \textit{MNX1} cause neonatal diabetes. This confirms a key role for \textit{NKX2-2} and \textit{MNX1} in human pancreatic development. Comparisons of phenotypes observed in humans and mice with inactivation of transcription factor genes supports common steps critical for pancreatic development. This study validates the use of knockout mice for understanding beta cell development in humans.

**EXPERIMENTAL PROCEDURES**

**Cohort**

We recruited 147 patients from consanguineous pedigrees (parents of the proband were second cousins or more closely related) who were diagnosed with permanent diabetes before 6 months of age or were diagnosed with permanent diabetes before 9 months and had any additional clinical features that made a diagnosis of type 1 diabetes less likely. Informed consent was
Table 3. A Comparison of the Phenotype Observed in the Patients with Homozygous Mutations in Known Pancreatic Transcription Factors to the Phenotype Observed in Homozygous Inactivation in Mice

| Gene   | Mutation   | Patient Phenotype | Mouse Phenotype | References                                                                 |
|--------|------------|-------------------|-----------------|---------------------------------------------------------------------------|
| GCK    | p.R1349C   | neonatal diabetes | null: neonatal   |                                                                                   |
|        |            |                   | diabetes        |                                                                                   |
|       |            | renal cystic dysplasia, | null: neonatal   |                                                                                   |
|        |            | congenital hypothyroidism, | diabetes        |                                                                                   |
|        |            | hepatic fibrosis    | knee flexion    |                                                                                   |
|        | p.R176Q    | null: pancreatic agenesis | null: pancreatic agenesis |                                                                                   |
|        |            | hypomorphic mutation: | hypomorphic mutation: |                                                                                   |
|        |            | neonatal diabetes  | neonatal diabetes|                                                                                   |
|        | p.S217P    | null: neonatal diabetes | null: neonatal diabetes |                                                                                   |
|        |            | duodenal atresia    | null: small bowel atresia |                                                                                   |
|        |            | gall bladder agenesis|                 |                                                                                   |

Some patients have been reported previously by Dimitri et al. (2011), Rubio-Cabezas et al. (2010), De Franco et al. (2013), Lango Allen et al. (2012), and Smith et al. (2010).

Exclusion of Nontranscription Factor Mutations in PNDM

To detect mutations in non-transcription factor genes that cause PNDM, we used Sanger sequencing (ABCC8, KCNJ11, INS) in all patients, followed by homozygosity mapping with sequencing of known genes (EIF2AK3, GLIS3, RFX6, P4HB, INS, G6PC3, PDX1, PTF1A, PTP4A3, KCNQ1, SMAD4, and SUSD4) within homozygous regions >3 Mb.

Detecting Mutations of Pancreatic Transcription Factor Genes

From published literature, we identified 29 transcription factor genes crucial for murine pancreatic development (Seymour and Sander, 2011; Zaret and Grompe, 2008) (Table 1). We identified homozygous regions through genome-wide single-nucleotide polymorphism (SNP) genotyping and used Sanger sequencing to detect mutations within homozygous regions encompassing these genes.

Genome-wide SNP Analysis to Localize Etiological Genes by Linkage

Genotyping was undertaken on the Affymetrix 10K, 500K, or v6.0 SNP chips by Medical Solutions, ALMAC Diagnostics, or AROS Applied Biotechnology. Processing of genomic DNA was performed as per the Affymetrix protocol, and in-house Perl scripts were developed to identify regions of significant homozygosity (>3 Mb) as previously described (Flanagan et al., 2011).

Sequencing of Pancreatic Transcription Factor Genes

When a large homozygous region encompassing one of the pancreatic transcription factor genes was identified, the coding regions and intron and exon boundaries of the gene were sequenced (Table 1, Figure S1, and Tables S2 and S3). Details of PCR primers and sequencing conditions are available on request. Pathogenicity was assessed on the basis of the characteristics of the mutation, the conservation of the affected amino acid, the absence from variant databases (accessed using Alamut v.2 Interactive Biosoftware), and cosegregation within families.

Patient Phenotype Assessment

For patients with homozygous mutations, their phenotype (both pancreatic and extrapancreatic) was compared with the phenotype of the knockout mouse for the same gene.

SUPPLEMENTAL INFORMATION

Supplemental Information includes one figure and three tables and can be found with this article online at http://dx.doi.org/10.1016/j.cmet.2013.11.021.

ACKNOWLEDGMENTS

The authors thank Annet Damhuis for technical assistance. O.R.-C. holds a “Miguel Servet” Research Fellowship funded by the Instituto de Salud Carlos III (CP11/00253). A.T.H. and S.E. are both employed as core members of the Exeter NIHR Clinical Research Facility, A.T.H. is an NIHR Senior Investigator. This work was funded by the Wellcome Trust (098395/Z/12/Z), Diabetes UK, and the European Community’s Seventh Framework Programme (FP7/2007-2013), grant agreement number FP7-PEOPLE-ITN-2008 (Marie Curie ITN, BOLD). The authors declare no conflict of interest.
REFERENCES

Al-Shammari, M., Al-Husain, M., Al-Kharfy, T., and Akuraya, F.S. (2011). A novel PTF1A mutation in a patient with severe pancreatic and cerebellar involvement. Clin. Genet. 80, 196–198.

Arber, S., Han, B., Mendelsohn, M., Smith, M., Jessell, T.M., and Sockanathan, S. (1999). Requirement for the homeobox gene Hb9 in the consolidation of motor neuron identity. Neuron 23, 659–674.

Bingham, C., Bulman, M.P., Ellard, S., Allen, L.I., Lipkin, G.W., Hoft, W.G., Woolf, A.S., Rizzoni, G., Novelli, G., Nicholl, A.J., and Hattersley, A.T. (2001). Mutations in the hepatocyte nuclear factor-1beta gene are associated with familial hypoplastic glomerulocystic kidney disease. Am. J. Hum. Genet. 68, 219–224.

Bonnefond, A., Vaillant, E., Philippe, J., Skrobek, B., Lobbens, S., Yengo, L., Huyvaert, M., Cavé, H., Busias, K., Scharfmann, R., et al. (2013). Transcription factor gene MNX1 is a novel cause of permanent neonatal diabetes in a consanguineous family. Diabetes Metab. 39, 276–280.

Briscoe, J., Sussel, L., Serup, P., Hartigan-O’Connor, D., Jessell, T.M., Rubenstein, J.L., and Ericson, J. (1999). Homeobox gene Nkx2.2 and specification of neuronal identity by graded Sonic hedgehog signalling. Nature 398, 622–627.

Cumarrino, G., Colín, D., and Votteler, T. (1981). Triad of anorectal, sacral, and presacral anomalies. AJR Am. J. Roentgenol. 137, 395–398.

De Franco, E., Shaw–Smith, C., Flanagan, S.E., Edghill, E.L., Wolf, J., Otte, V., Ebbing, F., Varthakavi, P., Vasanthi, T., Edvardsson, S., et al. (2013). Biallelic PDX1 (insulin promoter factor 1) mutations causing neonatal diabetes without exocrine pancreatic insufficiency. Diabet. Med. 30, e197–e200.

De Vos, A., Heimberg, H., Quartier, E., Huybens, P., Bouwens, L., Pipeleers, D., and Schuit, F. (1995). Human and rat beta cells differ in glucose transporter expression but not in glucokinase gene expression. J. Clin. Invest. 96, 2489–2495.

Delepine, M., Nicolino, M., Barrett, T., Golamaully, M., Lathrop, G.M., and D., and Schuit, F. (1995). Human and rat beta cells differ in glucose transporter expression but not in glucokinase gene expression. J. Clin. Invest. 96, 2489–2495.

Fajans, S.S., Bell, G.I., Paz, V.P., Below, J.E., Cox, N.J., Martin, C., Thomas, I.H., and Chen, M. (2010). Obesity and hyperinsulinemia in a family with pancreatic agenesis and MODY caused by the IPF1 mutation Pro63fsX60. Transl. Res. 156, 7–14.

Flanagan, S.E., Patch, A.M., Locke, J.M., Akcyay, T., Simsek, E., Alaei, M., Yeka, Z., Desai, M., Kapoor, R.R., Hussain, K., and Ellard, S. (2011). Genome-wide homozygosity analysis reveals HADH mutations as a common cause of diazoxide-resistant hyperinsulinemic-hypoglycemia in consanguineous pedigrees. J. Clin. Endocrinol. Metab. 96, E498–E502.

Fukuda, A., Kawaguchi, Y., Furuyama, K., Kodama, S., Horiguchi, M., Kuhara, T., Kawaguchi, M., Tsai, M.J., Doi, R., Wright, C.V., and et al. (2008). Reduction of Ptf1a gene dosage causes pancreatic hypoplasia and diabetes in mice. Diabetes 57, 2421–2431.

Harding, H.P., Zeng, H., Zhang, Y., Jungris, R., Chung, P., Plesken, H., Sabatini, D.D., and Ron, D. (2001). Diabetes mellitus and exocrine pancreatic dysfunction in perk/– mice reveals a role for translational control in secretory cell survival. Mol. Cell 7, 1153–1163.

Harrison, K.A., Thaler, J., Pfaff, S.L., Gu, H., and Kehri, J.H. (1999). Pancreas dorsal lobe agenesis and abnoraml islets of Langerhans in Hhob8-deficient mice. Nat. Genet. 23, 71–75.

Haumatte, C., Barbacci, E., Josselin, M., Ott, M.O., Gradwohl, G., and Cereghini, S. (2005). Lack of TCF2/HNF1 in mice leads to pancreas agenesis. Proc. Natl. Acad. Sci. USA 102, 1490–1495.

Hoshino, M., Nakamura, S., Mori, K., Kawachi, T., Terai, M., Nishimura, Y.V., Fukuda, A., Fuse, T., Matsu, N., Sone, M., et al. (2005). Ptf1a, a bHLH trans-

scriptional gene, defines GABAergic neuronal fates in cerebellum. Neuron 47, 201–213.

Jonsson, J., Carlsson, L., Edlund, T., and Edlund, H. (1994). Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 371, 606–609.

Kawaguchi, Y., Cooper, B., Gannon, M., Ray, M., MacDonald, R.J., and Wright, C.V. (2002). The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat. Genet. 32, 128–134.

Kim, W.Y., Fritzsche, B., Bier, N.A., Huang, E.J., Reichardt, L.F., Barth, D.S., and Lee, J.E. (2001). NeuroD-null mice are deaf due to a severe loss of the inner ear sensory neurons during development. Development 128, 417–426.

Köchling, J., Karbasiyan, M., and Reis, A. (2001). Spectrum of mutations and genotype-phenotype analysis in Currarino syndrome. Eur. J. Hum. Genet. 9, 599–605.

Kropp, A., Knötler, M., Ledermann, B., Bürki, K., Bemelm, C., Zerker, N., Hagenböčle, O., and Wellauer, P.K. (1998). BHLH protein PTF1-p48 is essential for the formation of the exocrine and the correct spatial organization of the endocrine pancreas. Genes Dev. 12, 3752–3763.

Kroon, E., Martinson, L.A., Kadoka, Y., Bang, A.G., Kelly, O.G., Eliazer, S., Young, H., Richardson, M., Smart, N.G., Cunningham, J., et al. (2008). Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat. Biotechnol. 26, 443–452.

Lango Allen, H., Flanagan, S.E., Shaw-Smith, C., De Franco, E., Akerman, I., Caswell, R., Ferrer, J., Hattersley, A.T., and Ellard, S.; International Pancreatic Agenesis Consortium (2012). GATA6 haploinsufficiency causes pancreatic agenesis in humans. Nat. Genet. 44, 20–22.

Liu, M., Pleasure, S.J., Collins, A.E., Noebels, J.L., Naya, F.J., Tsai, M.J., and Lowenstein, D.H. (2000). Loss of BET2/NeuroD leads to malformation of the dentate gyrus and epilepsy. Proc. Natl. Acad. Sci. USA 97, 865–870.

McCulloch, L.J., de la B, Braun, M., Frayn, K.N., Clark, A., and Gloyon, A.L. (2011). GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus. Mol. Genet. Metab. 104, 648–653.

Miya, T., Maeda, T., and Lee, J.E. (1999). NeuroD is required for differentiation of the granule cells in the cerebellum and hippocampus. Genes Dev. 13, 1647–1652.

Morrissey, E., Tang, Z., Sigrist, K., Lu, M.M., Jiang, F., Ip, H.S., and Parmacek, M.S. (1998). GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in the mouse embryo. Genes Dev. 12, 3579–3590.

Morrow, E.M., Furukawa, T., Lee, J.E., and Cepko, C.L. (1999). NeuroD regulates multiple functions in the developing neural retina in rodent. Development 126, 23–36.

Naya, F.J., Huang, H.P., Qu, Y., Mutoh, H., DeMayo, F.J., Leiter, A.B., and Tsai, M.J. (1997). Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BET2/neuroD-deficient mice. Genes Dev. 11, 2323–2334.

Nicolino, M., Claborn, K.C., Sené, B., Boland, A., Stoffers, D.A., and Julier, C. (2010). A novel hypomorphic PDX1 mutation responsible for permanent neonatal diabetes with subclinical exocrine deficiency. Diabetes 59, 733–740.

Olfeld, M.F., Jetton, T.L., Gabosky, P.A., Ray, M., Stein, R.W., Magnuson, M.A., Holter, A., et al. (2001). Neonatal diabetes mellitus due to complete glucokinase deficiency. N. Engl. J. Med. 344, 1588–1592.

Oliver-Krasinski, J.M., Kasner, M.T., Yang, J., Crutchlow, M.F., Rustgi, A.K., Kaestner, K.H., and Stoffers, D.A. (2009). The diabetes gene Pdx1 regulates the transcriptional network of pancreatic endocrine progenitor cells in mice. J. Clin. Invest. 119, 1888–1898.
Pennesi, M.E., Cho, J.H., Yang, Z., Wu, S.H., Zhang, J., Wu, S.M., and Tsai, M.J. (2003). BET2/NeuroD1 null mice: a new model for transcription factor-dependent photoreceptor degeneration. J. Neurosci. 23, 453–461.

Qi, Y., Cai, J., Wu, Y., Wu, R., Li, J., Fu, H., Rao, M., Susset, L., Rubenstein, J., and Qiu, M. (2001). Control of oligodendrocyte differentiation by the Nkx2.2 homeodomain transcription factor. Development 128, 2723–2733.

Ross, A.J., Ruiz-Perez, V., Wang, Y., Hagan, D.M., Scherer, S., Lynch, S.A., Lindsay, S., Custard, E., Belloni, E., Wilson, D.I., et al. (1998). A homeobox gene, HLB9, is the major locus for dominantly inherited sacral agenesis. Nat. Genet. 20, 358–361.

Rubio-Cabezas, O., Patch, A.M., Minton, J.A., Flanagam, S.E., Edghill, E.L., Hussain, K., Balafrej, A., Deeb, A., Buchanan, C.R., Jefferson, I.G., et al. (2010). Homozygous mutations in NEUROD1 are responsible for a novel syndrome of permanent neonatal diabetes mellitus and neurological abnormalities. Diabetes 59, 2326–2331.

Rubio-Cabezas, O., Jensen, J.N., Hodgson, M.I., Coodner, E., Ellard, S., Serup, P., and Hattersley, A.T. (2011). Permanent Neonatal Diabetes and Enteric Anodcrinosis Associated With Biallelic Mutations in NEUROG3. Diabetes 60, 1349–1353.

Schwitzgebel, V.M., Mamin, A., Brun, T., Ritz-Laser, B., Zaiko, M., Maret, A., Rabin, R.A., Rubenstein, J.L., and German, M.S. (1998). Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. Development 125, 2213–2221.

Terauchi, Y., Sakura, H., Yasuda, K., Iwamoto, K., Takahashi, N., Ito, K., Kasai, H., Suzuki, H., Ueda, O., Kamada, N., et al. (1995). Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J. Biol. Chem. 270, 30253–30256.

Thaler, J., Harrison, K., Sharma, K., Lettieri, K., Kehri, J., and Pfaff, S.L. (1999). Active suppression of interneuron programs within developing motor neurons revealed by analysis of homeodomain factor H9B. Neuron 23, 675–687.

Thomas, P.M., Cote, G.J., Wohllik, N., Haddad, B., Mathew, P.M., Rabi, W., Aguilar-Bryan, L., Gagel, R.F., and Bryan, J. (1995). Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 268, 426–429.

Thomas, I.H., Saini, N.K., Adhikari, A., Lee, J.M., Kasa-Vubu, J.Z., Vazquez, D.M., Monen, R.K., Chen, M., and Fajans, S.S. (2009). Neonatal Diabetes mellitus with pancreatic agenesis in an infant with homozygous IPF-1 Pro63fsX60 mutation. Pediatr. Diabetes 10, 492–496.

Watanabe, N., Hiramatsu, K., Miyamoto, R., Yasuda, K., Suzuki, N., Oshima, N., Kiyonari, H., Shibata, D., Nishio, S., Mochizuki, T., et al. (2009). A murine model of neonatal diabetes mellitus in Glis3-deficient mice. FEBS Lett. 583, 2108–2113.

Zaret, K.S., and Grome, M. (2008). Generation and regeneration of cells of the liver and pancreas. Science 322, 1490–1494.

Zhang, P., McGrath, B., Li, S., Frank, A., Zambito, F., Reinert, J., Gannon, M., Ma, K., McNaughton, K., and Cavener, D.R. (2002). The PERK eukaryotic initiation factor 2 alpha kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. Mol. Cell. Biol. 22, 3864–3874.

Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J., and Melton, D.A. (2008). In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455, 627–632.